stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Net income
Arrowhead Pharmaceuticals, Inc.'s net income for fiscal 2025 was $30.1M, compared with −$609.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$272.1M. Over the past ten years it has ranged from −$609.7M (fiscal 2024) to $68.0M (fiscal 2019); the current reading is higher than 91% of that period. Arrowhead Pharmaceuticals, Inc. ranks 552nd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $30.1M | — |
| FY2024 | −$609.7M | — |
| FY2023 | −$209.3M | — |
| FY2022 | −$176.5M | — |
| FY2021 | −$140.8M | — |
| FY2020 | −$84.6M | — |
| FY2019 | $68.0M | — |
| FY2018 | −$54.5M | — |
| FY2017 | −$34.4M | — |
| FY2016 | −$81.7M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$178.9M | — |
| Mar 2026 | −$137.6M | — |
| Dec 2025 | $28.2M | 75.19% |
| Sep 2025 | $16.1M | — |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $225.2M |
| CORT Corcept Therapeutics Incorporated compare | $162.3M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| ARWR Arrowhead Pharmaceuticals, Inc. | −$272.1M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ARWR
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement